Join the Weight Loss (Obesity / Overweight) group to help and get support from people like you.
Weight Loss (Obesity / Overweight) News (Page 2)
Related terms: Weight Gain, Overweight, Weightloss, Anorexiants, Obesity, Obese, Weight Loss, Loose Weight, Lost Weight, diet drugs, diet medications, anti-obesity medications, Weight Loss Medications
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
MONDAY, May 12, 2025 — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The study — published May 11 in th...
Childhood Obesity Triples Odds Of Weight Discrimination
FRIDAY, May 9, 2025 — Childhood obesity nearly triples a person’s risk for experiencing discrimination or stigma based on their weight, a new study says. Severe obesity before age 18 increased a per...
Simultaneous Liver Transplant, Sleeve Gastrectomy Beneficial
FRIDAY, May 9, 2025 – Simultaneous liver transplant and sleeve gastrectomy (LTSG) yield durable weight loss, resolution of diabetes and hypertension, and a reduction in allograft steatosis...
Hyperglycemia, Insulin Resistance in Teens Linked to Worsening Cardiac Damage at Age 24
FRIDAY, May 9, 2025 – Adolescent hyperglycemia and worsening insulin resistance (IR) are associated with an increased risk for worsening structural and functional cardiac damage, according to a...
Body Mass Index (BMI): What It Tells You — And What It Doesn’t
SUNDAY, May 4, 2025 — Body Mass Index, or BMI, is a number that reflects the relationship between your height and weight. It's widely used in healthcare and public health to categorize body size and e...
Metformin Beneficial for Osteoarthritis Knee Pain in Overweight, Obesity
THURSDAY, May 1, 2025 – For patients with overweight or obesity and symptomatic knee osteoarthritis, metformin is associated with a greater improvement in knee pain than placebo, according to a...
New HHS Ad Campaign Urges Americans to 'Take Back Your Health'
WEDNESDAY, April 30, 2025 — U.S. Health and Human Services Secretary Robert F. Kennedy Jr. is preparing to launch a multimillion-dollar public health campaign, according to documents reviewed by NBC N...
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 – Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and...
Lifestyle Poses Greatest Risk For Cardiac Arrest
TUESDAY, April 29, 2025 – Nearly two-thirds of cardiac arrest cases could be prevented by managing lifestyle, environmental and personal health risks, a new study says. Researchers found that...
FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic
MONDAY, April 21, 2025 – The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic (semaglutide) and to...
Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk
MONDAY, April 21, 2025 – Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in midlife, according to a...
First Weight-Loss Pill From Lilly, Orforglipron, Shows Promising Results
FRIDAY, April 18, 2025 — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its experimental drug, orforglipron, helped people w...
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 – The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a...
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 – After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without...
Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury
TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went ...
Further information
Related drug support groups
bupropion, phentermine, Contrave, Ozempic, amphetamine, Saxenda, methamphetamine, Mounjaro, topiramate, view more... Wegovy, semaglutide, methylphenidate, Qsymia, Zepbound, liraglutide, tirzepatide, Adipex-P, Alli, orlistat, garcinia cambogia, desvenlafaxine, dulaglutide